CA-RUBICON-CARBON
9.7.2024 15:01:29 CEST | Business Wire | Press release
Rubicon Carbon, a carbon credit management firm, today announced a new partnership with Formula E Champion and ABT CUPRA driver Lucas di Grassi to purchase carbon credits using the company’s platform. Di Grassi is the first Formula E driver to offset his carbon footprint by personally investing in carbon credits.
Di Grassi built his own Rubicon Carbon Tonne (RCT), a diversified and actively managed portfolio of carbon credits that includes carbon removal, nature-based avoidance, and industrial avoidance projects. Through RCTs, buyers reduce risk and increase optionality and price certainty.
"We are excited to support Lucas and Formula E, who share our values in building a low-carbon future," said Tom Montag, CEO of Rubicon Carbon. "This partnership perfectly aligns with our mission to innovate and lead in the fight against climate change, and we look forward to helping Lucas on his path to decarbonizing the mobility and racing industries.”
To celebrate the partnership, di Grassi’s car and helmet proudly displayed Rubicon Carbon logos at last month’s Hankook Portland E-Prix in Portland, Oregon. The collaboration between Rubicon Carbon and di Grassi exemplifies the potential of sports partnerships to drive positive environmental change.
As an activist in mobility technology and the first Formula E driver to publicly sever ties with industries that do not prioritize sustainability, di Grassi has set a precedent for how to champion environmental responsibility as a professional athlete.
Speaking on the partnership, di Grassi noted, “I am proud to be the first driver to offset all the carbon I have emitted from traveling around the world since my first Formula E race in Beijing. Working with (Rubicon Carbon CEO) Tom Montag and his entire team is the perfect partnership for me, as Rubicon Carbon is the most qualified and credible carbon credit management firm in the world. In line with the values and objectives of Formula E, I drive an electric car and have adapted my lifestyle. But still, credible carbon avoidance and removal is the only way to do the sport we love and be responsible for our environment at the same time. I would be delighted if many other athletes, not only in Formula E, would consider the same path.”
This partnership follows Rubicon’s recent investments in carbon projects across the globe, including a large-scale ecosystem restoration project in Panama in partnership with Ponterra, Microsoft, and Carbon Streaming, a 250K+ acres restoration project in South Africa led by Imperative, and a collaboration with YvY Capital to scale up carbon investments in Brazil.
For more information on Rubicon Carbon, visit the website or follow on LinkedIn.
About Lucas di Grassi:
Lucas di Grassi is a founding member of Formula E, has competed in every race up until now and is the most successful driver on the grid in terms of podium positions. He was winner of the first ever race in Beijing 2014, Champion in the 2016/2017 and teams' Champion in 2017/2018. In addition to his role as an ABT CUPRA driver, Lucas di Grassi is an entrepreneur for innovation, sustainability and electric mobility. As co-founder of Zero Summit he is organizing technology and business panels for a zero-carbon future in many countries around the world. Since 2018, Lucas di Grassi is an official United Nations Ambassador for Clean Air. Lucas di Grassi lives in Monaco together with his wife Bianca, his son Leonardo and his daughter Beatriz.
About Formula E:
As the world’s first all-electric FIA World Championship and the only sport certified net zero carbon since inception, the ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation. The Formula E network of teams, manufacturers, partners, broadcasters, and host cities are united by a passion for the sport and belief in its potential to accelerate sustainable human progress and create a better future for people and planet.
About Rubicon Carbon:
Rubicon Carbon is a carbon credit management firm that partners with the world’s largest enterprises to help them achieve their sustainability goals while driving global decarbonization. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking decarbonization projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit www.rubiconcarbon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709047754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom